Michael A Kraus proposed to the board of Redsense Medical AB
Idag, 10:00
Michael A Kraus proposed to the board of Redsense Medical AB
Halmstad, Sweden, March 10, 2026 – Redsense Medical AB (publ) (“Redsense'' or “the Company”) announces that the Company’s Nomination Committee proposes that Michael A Kraus be elected as a new board member at the annual general meeting on May 20, 2026.
Michael A Kraus is a nephrologist with 35 years of experience. He trained at the University of Iowa and later held faculty positions there as well as at Indiana University. He served at Indiana University for 25 years, rising to the rank of Clinical Professor and Clinical Chief. Michael later joined the dialysis industry as Associate Chief Medical Officer at NxStage Medical and Fresenius Kidney Care. Dr. Kraus is a recognized leader in CRRT, home dialysis, and ESKD care, with extensive experience in patient care, administration, and government relations. He has authored numerous manuscripts and book chapters and is an internationally recognized speaker.
Michael holds an AB degree from Wabash College, MD from Indiana University, Indianapolis Indiana. Other assignments are Chief Medical Director at Indiana Donor Network (Organ Procurement Organization)Emeritus Professor of Clinical Medicine – Indiana University School of Medicine.
Michael A Kraus is independent of the company and it’s management and major shareholders.
The nomination committee's other proposals will be announced in the notice of the Annual General Meeting to be held in Halmstad on May 20, 2026.
Susanne Olauson
Chairwoman of the Nomination Committee
Telefon: +46 (0) 73-230 9708
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS)
Contact information
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862
Ämnen i artikeln
Michael A Kraus proposed to the board of Redsense Medical AB
Idag, 10:00
Michael A Kraus proposed to the board of Redsense Medical AB
Halmstad, Sweden, March 10, 2026 – Redsense Medical AB (publ) (“Redsense'' or “the Company”) announces that the Company’s Nomination Committee proposes that Michael A Kraus be elected as a new board member at the annual general meeting on May 20, 2026.
Michael A Kraus is a nephrologist with 35 years of experience. He trained at the University of Iowa and later held faculty positions there as well as at Indiana University. He served at Indiana University for 25 years, rising to the rank of Clinical Professor and Clinical Chief. Michael later joined the dialysis industry as Associate Chief Medical Officer at NxStage Medical and Fresenius Kidney Care. Dr. Kraus is a recognized leader in CRRT, home dialysis, and ESKD care, with extensive experience in patient care, administration, and government relations. He has authored numerous manuscripts and book chapters and is an internationally recognized speaker.
Michael holds an AB degree from Wabash College, MD from Indiana University, Indianapolis Indiana. Other assignments are Chief Medical Director at Indiana Donor Network (Organ Procurement Organization)Emeritus Professor of Clinical Medicine – Indiana University School of Medicine.
Michael A Kraus is independent of the company and it’s management and major shareholders.
The nomination committee's other proposals will be announced in the notice of the Annual General Meeting to be held in Halmstad on May 20, 2026.
Susanne Olauson
Chairwoman of the Nomination Committee
Telefon: +46 (0) 73-230 9708
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS)
Contact information
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862
Ämnen i artikeln
Oljepriset
Oljepriset
Marknadsöversikt
1 DAG %
Senast
1 mån
